Gyroscope Therapeutics Holdings plc announced that it will receive up to £44.5 million in an equity round of funding from new investor, Sanofi Ventures on November 8, 2021. The investor will invest £29.666666 million initially, at a premium to company's prior Series C financing, and the remaining £14.833333 million will be invested contingent on a future qualifying investment round and subject to the satisfaction of certain closing conditions. As a part of the transaction, a Sanofi R&D executive will join the company's Clinical Advisory Board.